Western study of arsenic trioxide (As2O3) in patients with relapsed and/or refractory acute promyelocytic leukemia

被引：0
|
作者：
Soignet, SL [1 ]
Maslak, P [1 ]
Chen, YW [1 ]
Calleja, E [1 ]
Pandolfi, PP [1 ]
Scheinberg, DA [1 ]
Warrell, RP [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
ANNALS OF ONCOLOGY | 1998年 / 9卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
675
引用
收藏
页码：176 / 176
页数：1
相关论文
共 50 条
  • [1] The use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia
    Zhang, P
    JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 1999, 13 (04): : 195 - 200
  • [2] Arsenic trioxide in the treatment of relapsed and refractory acute promyelocytic leukemia
    Asou, N
    INTERNAL MEDICINE, 2005, 44 (08) : 775 - 776
  • [3] Arsenic trioxide therapy for relapsed or refractory Japanese patients with acute promyelocytic leukemia
    Shigeno, K
    Nakamura, S
    Naito, K
    Yoshida, H
    Fujisawa, S
    Shinjo, K
    Fujita, Y
    Matsui, H
    Sahara, N
    Takeshita, A
    Ohno, R
    Ohnishi, K
    BLOOD, 2002, 100 (11) : 264B - 264B
  • [4] Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APE) .2. Clinical efficacy and pharmacokinetics in relapsed patients
    Shen, ZX
    Chen, GQ
    Ni, JH
    Li, XS
    Xiong, SM
    Qiu, QY
    Zhu, J
    Tang, W
    Sun, GL
    Yang, KQ
    Chen, Y
    Zhou, L
    Fang, ZW
    Wang, YT
    Ma, J
    Zhang, P
    Zhang, TD
    Chen, SJ
    Chen, Z
    Wang, ZY
    BLOOD, 1997, 89 (09) : 3354 - 3360
  • [5] Pharmacokinetics of arsenic trioxide (ATO) in patients with relapsed/refractory acute promyelocytic leukemia (APL).
    Soignet, S
    Bienvenu, B
    Warrell, RP
    Ellisson, R
    Spriggs, D
    Brannan, M
    CLINICAL CANCER RESEARCH, 2000, 6 : 4534S - 4534S
  • [6] Pathologic, cytogenetic and molecular assessment of acute promyelocytic leukemia patients treated with arsenic trioxide (As2O3)
    Zhang, T
    Westervelt, P
    Hess, JL
    MODERN PATHOLOGY, 2000, 13 (09) : 954 - 961
  • [7] Pharmacokinetics of arsenic species in Japanese patients with relapsed or refractory acute promyelocytic leukemia treated with arsenic trioxide
    Fujisawa, Shinya
    Ohno, Ryuzo
    Shigeno, Kazuyuki
    Sahara, Naohi
    Nakamura, Satoki
    Naito, Kensuke
    Kobayashi, Miki
    Shinjo, Kaori
    Takeshita, Akihiro
    Suzuki, Yoshinari
    Hashimoto, Hisakuni
    Kinoshita, Kenji
    Shimoya, Masahito
    Kaise, Toshikazu
    Ohnishi, Kazunori
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2007, 59 (04) : 485 - 493
  • [8] Pharmacokinetics of arsenic species in Japanese patients with relapsed or refractory acute promyelocytic leukemia treated with arsenic trioxide
    Shinya Fujisawa
    Ryuzo Ohno
    Kazuyuki Shigeno
    Naohi Sahara
    Satoki Nakamura
    Kensuke Naito
    Miki Kobayashi
    Kaori Shinjo
    Akihiro Takeshita
    Yoshinari Suzuki
    Hisakuni Hashimoto
    Kenji Kinoshita
    Masahito Shimoya
    Toshikazu Kaise
    Kazunori Ohnishi
    Cancer Chemotherapy and Pharmacology, 2007, 59 : 485 - 493
  • [9] Pathologic, cytogenetic and molecular assessment of acute promyelocytic leukemia (APL) patients treated with arsenic trioxide (As2O3,)
    Zhang, T
    Westervelt, P
    Hess, JL
    LABORATORY INVESTIGATION, 1999, 79 (01) : 150A - 150A
  • [10] Oral arsenic trioxide for relapsed acute promyelocytic leukemia in pediatric patients
    Au, Wing Y.
    Li, Chi-Kong
    Lee, Vincent
    Yuen, Hui Leung
    Yau, Jeffrey
    Chan, Godfrey C. F.
    Ha, Shau-yin
    Kwong, Yok-lam
    PEDIATRIC BLOOD & CANCER, 2012, 58 (04) : 630 - 632
12345